Key appointments include Robert John as Chief Revenue Officer, bringing over 25 years of sales leadership experience in the medical device industry; Dr. Philip Adamson as Chief Medical Officer; Bonnie Handke as SVP of Patient Access, Reimbursement, and Healthcare Economics; Jennifer Englund as SVP of Global Clinical Research to enhance clinical evidence; and Tonya Austin as Chief Human Resources Officer. These strategic hires position CVRx to effectively address awareness, clinical, and patient access barriers as it drives Barostim towards becoming standard of care for heart failure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVRX:
- CVRx Reports Second Quarter 2024 Financial and Operating Results
- CVRX Earnings this Week: How Will it Perform?
- CVRx to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call on July 29th, 2024
- CVRx price target lowered to $15 from $23 at Craig-Hallum
- CVRx price target lowered to $12 from $18 at Lake Street